Vannair 80:4,5 80 μg, 160 μg Inhaler
PDF Leaflet Revision Date: 16 October 2020
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of asthma and COPD.
Dosage (summary)
Adults: 2 inhalations twice daily; max 4 inhalations if needed.
Onset of Action / Duration
Onset: 1-3 mins, Duration: up to 12 hours.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Safety not established; use with caution in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- Beta-adrenergic blockers
- QT prolonging agents
Contraindications
- Hypersensitivity to budesonide or formoterol
Common side effects
- Palpitations
- Tremor
- Headache
- Coughing
- Hoarseness
Counselling Points
- Use regularly even if asymptomatic
- Have a rescue inhaler available
- Rinse mouth after use
Serious warnings
- Not for acute exacerbations
- Risk of pneumonia in COPD
- Monitor growth in children
Important Disclaimer
The Vannair 80:4,5 80 μg, 160 μg Inhaler professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
